@article{article, title  = {{Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)}},

 publisher = {{Springer Nature}},

 url = {{}},

 year = {{2022}},

 month = {{5}},

 author = {{Blauvelt A and Guttman-Yassky E and Paller AS and Simpson EL and Cork MJ and Weisman J and Browning J and Soong W and Sun X and Chen Z and Kosloski MP et al}},

 doi = {{10.1007/s40257-022-00683-2}},

 volume = {{23}},

 journal = {{American Journal of Clinical Dermatology}},

 issue = {{3}},

 pages = {{365-383}},

 note = {{Accessed on 2024/12/22}}}